is a nonselective hydrazine
-derived monoamine oxidase inhibitor
used in treatment resistant depression
In the United States, isocarboxazid is approved for the treatment of depression, anxiety (panic disorder) with or without agoraphobia.
In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs).
A randomized controlled trial
published in December 1988 found that isocarboxazid significantly reduced bingeing
in bulimia nervosa
, regardless of the presence or absence of depression or personality disorder
by Hoffmann-La Roche
, starting in 1959
and discontinuing in 1994
. After much patient and physician outcry, they resumed manufacturing just enough Marplan
to distribute on an as-needed basis. In October of 1998
, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc.
announced that Oxford, "is acquiring ownership of the NDA
for the antidepressant
product Marplan (isocarboxazid) from Roche."
The maximum daily dose of isocarboxazid is 60mg.
Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF).